Reviews/Dry Eye Disease Treatment/Autologous serum improves severe refractory dry eye
Autologous Serum · DED-AS-01 · v2
Several separate randomised trials tested autologous serum drops, made from a patient's own blood, against artificial tears or other comparators in people with severe or treatment-resistant dry eye. Patients using serum drops consistently reported feeling better and had more stable tear films [6][7][11], and a large trial in moderate-to-severe disease found a clear symptom advantage for serum drops [1]. The improvement was most reliable for how patients felt; objective clinical signs such as tear production and surface staining improved less consistently and seemed to depend on how concentrated the serum was [5]. The strongest severe-refractory evidence comes from small studies, some lasting only two weeks, and one uncontrolled series in transplant-related dry eye [12]. The panel weighed a replicated symptom benefit against these weaknesses in objective signs, sample size and trial design.
Independent randomised trials report that autologous serum drops improve symptoms and tear-film stability in severe or refractory dry eye more than artificial tears [6][7][11]. Symptom gains are sizeable: [7] reports a 55.18% OSDI decrease with serum versus 19.50% with preservative-free artificial tears, [11] a 50% versus 22% OSDI decrease, and [1] an average OSDI difference of -10.3 (95% CI -13.6 to -7.0) favouring serum in moderate-to-severe disease. Objective signs are less uniform: [11] found no significant change in OXFORD staining or TBUT, and [7] found no significant difference in Schirmer or OXFORD scores. Concentration matters: in [5], AS20% failed to improve objective parameters in severe disease while AS50% performed better. Uncontrolled before-after data support benefit in severe GVHD-associated dry eye, with complaint scores falling from 33.7 to 23.6 (P<0.01) [12]. The contested point: The evidence divides along endpoint type: the symptom and tear-stability signal is consistent and replicated, but objective signs (Schirmer, OXFORD/corneal staining) are frequently non-significant versus control [7][11] and are concentration-dependent, with AS20% failing objectively in severe disease [5]. Whether serum drops change objective disease in the severe-refractory target population, as opposed to subjective comfort, is where the corpus and the panel diverge.
All 14 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Dry Eye Disease Treatment, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The positive signal concentrates on subjective symptom endpoints (OSDI/complaint scores); objective signs such as Schirmer and Oxford/corneal staining were frequently non-significant versus control ([7],[11],[2]), raising surrogate-indirectness and placebo-susceptibility concerns.
Trials demonstrating severe-refractory benefit are small and often short: [11] N=12, [7]/[6] N~20, [12] N=14, with [6] and [11] treating only 2 weeks — underpowered and unable to show durable benefit.
Where it remains uncertain. Objective signs often did not improve significantly versus control [7][11], and the common 20% concentration failed objectively in severe disease while 50% worked [5].
Aleatory
Severe-refractory trials are small ([11] N=12, [12] N=14, [7]/[6] N≈20), so chance variation can inflate or mask effects.
Epistemic
Several positive trials treated for only two weeks ([6][11]), leaving long-term benefit unestablished in controlled designs.
Inferential
Benefit rests largely on subjective OSDI/complaint scores while objective signs were often non-significant [7][11], weakening the inference to objective disease improvement.
The load-bearing papers from a corpus of 14, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Large multi-centre RCT quantifying AS symptom benefit over artificial tears in moderate-to-severe DES
“The average difference in the OSDI score between the two cohorts was -10.3 (95% confidence interval: -13.6 to -7.0), indicating a substantial improvement in the ASEDs group.”
Panel auditInternal validity: medium · scope of inference: Patients with moderate-to-severe dry eye syndrome at three Chinese clinics over 12 weeks.Key limitations: population moderate-to-severe not strictly severe refractory · masking not stated · 12-week horizon
Double-blind RCT showing AS effective in severe DES across clinical measures
“The three sera were effective in the treatment of severe DES.”
Panel auditInternal validity: medium · scope of inference: Patients with severe dry eye disease over three months.Key limitations: no non-serum control arm · improvement attributable to time not isolated serum effect · n=21 per arm
Qualifies the claim: objective benefit in severe DED is concentration-dependent (AS50% > AS20%)
“But in severe DED, the AS20% group failed to show any significant improvement objectively, though subjective improvement was present.”
Panel auditInternal validity: medium · scope of inference: Patients with moderate-to-severe dry eye refractory to conventional treatment, secondary Sjögren's being the commonest etiology.Key limitations: effect concentration-dependent · AS20% objectively non-significant in severe DED · no non-serum control · small sample
The head-to-head is serum versus another active blood product (no significant difference), not serum versus control, and within-group change was mixed with OSDI and Schirmer unchanged, so the abstract does not show serum beats no treatment.
Panel auditInternal validity: medium · scope of inference: Patients with primary Sjögren's syndrome dry eye over 12 weeks.Key limitations: comparator is PRP not control · small sample · OSDI and Schirmer unchanged · population not stated severe refractory
4 of 14 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Consistent, independently replicated symptom and tear-stability benefit in severe/refractory populations supports the claim, but surrogate-weighted endpoints, small underpowered samples, and concentration-dependent objective effects hold it below the Established band.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Objective-sign efficacy in severe refractory disease. The replicated benefit is on symptoms; objective signs (Schirmer, OXFORD/corneal staining) were frequently non-significant versus control [7][11], leaving objective disease modification unproven. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: Adequately powered double-blind RCT versus artificial tears in a strictly severe-refractory population with pre-specified objective primary endpoints.
Open question: Do autologous serum drops improve objective signs, not just symptoms, in a strictly severe-refractory population? Why it is still open: Controlled objective endpoints (Schirmer, OXFORD/corneal staining) were frequently non-significant [7][11].
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19